Clinical Trial Goal
To find out if the combination of mosunetuzumab and polatuzumab is safe and works well to treat follicular lymphoma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have follicular lymphoma that has relapsed or is refractory
- Have cancer cells with mutation/marker CD20 (CD20+). Your doctor can tell you this
- Do not have lymphoma in your brain or spinal cords
- Have not been treated with the following (your doctor can tell you this):
- Antibody drug conjugate containing MMAE
- CD20 bispecific antibody, like mosunetuzumab
- Have not had an allogeneic (cells from a donor) blood or marrow transplant (BMT) in the last 2 years
- Have not had an autologous BMT in the last 3 months
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Mosunetuzumab is a T-cell engaging bispecific antibody that target CD20 and CD3 on certain cells.
Polatuzumab is a monoclonal antibody-drug conjugate, or combination, that targets CD79b on certain cells.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
Polatuzumab is a monoclonal antibody-drug conjugate, or combination, that targets CD79b on certain cells.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
- Mosunetuzumab – Given as a shot under your skin up to 3 times
- Polatuzumab – Given as an intravenous (IV) infusion 1 time
You may continue treatment for up to about 1 year. You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 3 years.
The Food and Drug Administration (FDA) has approved mosunetuzumab to treat follicular lymphoma and polatuzumab to treat other lymphomas. Using them together in this way to treat follicular lymphoma is new and unproven.
Locations
City of Hope Orange County Lennar Foundation Cancer CenterNOT_YET_RECRUITING
Irvine, California
Azra Borogovac, MD, 949-844-1738, aborogovac@coh.org
City of Hope Medical CenterRECRUITING
Duarte, California
Matthew Mei, 626-256-4673, mamei@coh.org
Sponsors
collaborator: National Cancer Institute (NCI), lead: City of Hope Medical Center
